A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...

Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...